Home / Stocks / TAK

Takeda Pharmaceutical Co (TAK, Pharmaceuticals) Stock Valuation & Fair Value Significantly overvalued

Takeda Pharmaceutical Co (TAK, Pharmaceuticals) trades at a blended P/E of 49.0, about 57% above its historical normal valuation, with a forward growth estimate of 29.8% and a PEG of 1.65. Analysts' one-year estimates have been hit 18% of the time.

No quality score is published for this company, which is normal for insurers, banks and REITs. This rating reflects valuation, forecast return and analyst accuracy only. Ratings that cite business quality require one.

DATA AS OF 2026-09-21
Blended P/E
49.0
Normal P/E
31.2
PEG
1.65
Fwd growth
29.8%
Div yield
2.8%
RSI (14)
62.2
Neutral
Technical context
  • Price $18.81 at the 2026-09-23 close, 2.0% above the 20-day average ($18.45) and 5.9% above the 50-day ($17.77).
  • RSI (14) at 62.2.
  • 52-week range $13.23 to $19.05: the price is 1.3% below the high and 42.2% above the low.

The Street vs SeerForecast

Wall Street's mean price target for TAK is $22.28 across 3 analysts, 18.5% above the current price. Our SeerForecast read of the same stock, formed without analyst targets: significantly overvalued. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating has been significantly overvalued since 2026-09-19.

Blended P/E and rating by weekBlended P/E moved from 49.0 to 49.0 between 2026-09-19 and 2026-09-21, against a normal P/E of 31.2, with 0 rating changes over 2 recorded weeks.2026-09-19: P/E 49.0, Significantly overvalued (recalculated)2026-09-21: P/E 49.0, Significantly overvalued35.040.045.0Sep 19Sep 20Sep 21Normal P/E 31.2
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Ratings recorded live since 2026-09-21. Earlier points apply today's valuation rules to the metrics tickerseer archived that week.

WeekBlended P/EPremium to normal P/ERating
2026-09-19P/E 49.0+57%Significantly overvalued
2026-09-21P/E 49.0+57%Significantly overvalued ← now

Frequently asked questions

Is Takeda Pharmaceutical Co stock overvalued?

At a blended P/E of 49.0 versus its historical normal P/E of 31.2, Takeda Pharmaceutical Co trades about 57% above its typical valuation, with a PEG of 1.65 on 29.8% forward growth. tickerseer currently rates it significantly overvalued.

What is Takeda Pharmaceutical Co's fair value and PEG?

Takeda Pharmaceutical Co trades at a blended P/E of 49.0 against a historical normal P/E of 31.2, a PEG of 1.65, and a forward growth estimate of 29.8%.

Has tickerseer's rating of Takeda Pharmaceutical Co changed?

tickerseer's rating has been significantly overvalued since 2026-09-19.

What is the analyst price target for Takeda Pharmaceutical Co?

The mean Wall Street price target for Takeda Pharmaceutical Co is $22.28 across 3 analysts, 18.5% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Pharmaceuticals. Create a free account to see the full analysis: the SeerAI score, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track TAK free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.